CTD Reports Initial Data for Two Clinical Trials of Trappsol® Cyclo™
CTD Holdings, Inc., a clinical stage biotechnology company that develops cyclodextrin-based products for the treatment of disease with unmet medical
Category: CD derivatives
CDs in hydrogen storage
Hydrogen as clean and renewable energy source could replace fossil fuels, but the lack of method for efficient storage inhibits
DIMEB in biotechnology
Heptakis(2,6-di-O-methyl) beta-cyclodextrin is a single isomer with high solubility in cold water, but it crystallizes from water at increased temperatures.
The monograph of SBECD is official in the European Pharmacopeia
As of January 1st, 2019, besides the long valid (August 1st, 2012) monograph in USP NF for Betadex Sulfobutyl Ether
Cyclodextrin News Year in Review 2018
The CDNews blog was created in July and after a short period of trial it started in September. During this
Opinion leaders of CD society getting together in Budapest
In the recent two weeks, Cyclolab had the pleasure to welcome two prominent pioneers of cyclodextrin research, Prof. Loftsson from
Protecting groups: Strategies and Applications in Carbohyrate Chemistry
The new book edited by Prof. Sébastien Vidal (University of Lyon) contains 17 chapters on various strategies and applications including
Antibody-Targeted Cyclodextrin-Based Nanoparticles for siRNA Delivery
In the laboratory of C. M. O’Driscoll (University College Cork), an antibody targeted cyclodextrin-based siRNA delivery vector (CD.DSPE-PEGFab) was developed
NO-releasing cyclodextrins
Nitric oxide (NO) is a signaling molecule produced by almost all types of organisms ranging from bacteria to plants and
Mannose with anti-cancer effect
In a recently published Nature report it was investigated how tumor cells respond to different forms of sugar [1]. It